前沿生物涨2.02%，成交额1.04亿元，主力资金净流入552.66万元

Group 1 - The core viewpoint of the news highlights the recent stock performance and financial metrics of Frontier Biopharmaceuticals, indicating a significant increase in stock price and trading activity [1][2] - As of September 24, the stock price of Frontier Biopharmaceuticals rose by 2.02% to 15.15 CNY per share, with a total market capitalization of 5.675 billion CNY [1] - The company has seen a year-to-date stock price increase of 55.23%, with a recent 5-day increase of 1.68% and a 20-day decrease of 12.38% [1] Group 2 - Frontier Biopharmaceuticals, established on January 15, 2013, and listed on October 28, 2020, focuses on the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs [2] - The company has a patented anti-HIV drug and two drugs in clinical trials, showcasing its strong capabilities in long-acting peptide drug development and a comprehensive industry chain from drug discovery to sales [2] - The main revenue source for the company is the anti-HIV drug, accounting for 91.29% of total revenue, while other products contribute 8.71% [2] Group 3 - As of June 30, the number of shareholders for Frontier Biopharmaceuticals increased by 5.74% to 12,000, while the average circulating shares per person decreased by 5.43% to 31,095 shares [3] - For the first half of 2025, the company reported a revenue of 58.6398 million CNY, reflecting a year-on-year growth of 14.85%, while the net profit attributable to shareholders was -97.3526 million CNY, showing a 39.33% increase in losses compared to the previous year [3]